Download PDF
Diabetologie und Stoffwechsel 2024; 19(05): 345-355
DOI: 10.1055/a-2224-6860
CME-Fortbildung

Diabetes mellitus und kardiovaskuläre Prävention

Diabetes mellitus and cardiovascular prevention
Monika Kellerer
,
Hui Jing Qiu
› Further Information
Also available at
    Permissions and Reprints

Menschen mit Diabetes leiden überproportional häufig an Herz-Kreislauf-Erkrankungen. Nicht zuletzt deshalb liegt ein mindestens 2-fach erhöhtes Risiko für einen frühzeitigen Tod im Vergleich zu Menschen ohne Diabetes vor, und die Lebenserwartung ist im Durchschnitt um etwa 5–6 Jahre kürzer. Zur Prognoseverbesserung von Menschen mit Diabetes ist deswegen eine Reduzierung der kardiovaskulären Risikofaktoren unabdingbar.

Abstract

Diabetes mellitus is the most common metabolic disease with >500 million people affected worldwide and currently 8,7 million in Germany. About 90% of diabetes cases are due to type 2 diabetes mellitus (T2D). This form of diabetes is characterized by an increased release of proinflammatory adipokines, endothelial dysfunction and hyperglycemia, among others. Hypertension and dyslipidemia are also very commonly present. The prevalence of cardiovascular disease is about 2–3 times higher in T2D than in age-matched individuals without a diagnosis of diabetes. Cardiovascular mortality is also about twice as high in people with diabetes compared to a non-diabetic population. People with diabetes are therefore generally considered a high-risk cardiovascular group and require special attention in the diagnosis and treatment of cardiovascular disease. Contributing factors to reduce high cardiovascular risk include a healthy lifestyle, normalization of blood pressure, optimization of blood lipid levels, and specific diabetes therapy tailored to cardiovascular risk. This review addresses the specific treatment options for reducing cardiovascular risk in patients with diabetes mellitus.

Schlüsselwörter

Diabetes mellitus - kardiovaskuläres Risiko - kardiovaskuläre Prävention

Keywords

diabetes mellitus - cardiovascular risk - cardiovascular prevention


Publication History

Article published online:
09 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Schmidt C, Reitzle L, Paprott R. et al. Diabetes mellitus und Begleiterkrankungen – Querschnittstudie mit Kontrollgruppe anhand vertragsärztlicher Abrechnungsdaten. J Health Monitor 2021; 6: 20-36
    CrossrefSearch in Google Scholar
  • 2 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 9: 165-173
    CrossrefPubMedSearch in Google Scholar
  • 3 Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol 2023; 11: 731-742
    CrossrefPubMedSearch in Google Scholar
  • 4 Marx N, Federici M, Schütt K. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140
    CrossrefPubMedSearch in Google Scholar
  • 5 ESC (European Society of Cardiology) CVD Risk Calculation App. Accessed April 16, 2024 at: www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app
  • 6 Wing RR, Bahnson JL, Bray GA. et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
    PubMedSearch in Google Scholar
  • 7 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, clusterrandomised trial. Lancet 2018; 391: 541-551
    CrossrefPubMedSearch in Google Scholar
  • 8 Look Ahead Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016; 4: 913-921
    CrossrefPubMedSearch in Google Scholar
  • 9 Estruch R, Ros E, Salas-Salvadó J. et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018; 378: e34
    CrossrefPubMedSearch in Google Scholar
  • 10 Polsky S, Akturk HK. Alcohol Consumption, Diabetes Risk, and Cardiovascular Disease Within Diabetes. Curr Diab Rep 2017; 17: 136
    CrossrefPubMedSearch in Google Scholar
  • 11 Wood AM, Kaptoge S, Butterworth AS. et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599912 current drinkers in 83 prospective studies. Lancet 2018; 391: 1513-1523
    CrossrefPubMedSearch in Google Scholar
  • 12 Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290: 86-97
    CrossrefPubMedSearch in Google Scholar
  • 13 Wahid A, Manek N, Nichols M. et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc 2016; 5: e002495
    CrossrefPubMedSearch in Google Scholar
  • 14 Emdin CA, Rahimi K, Neal B. et al. Blood Pressure Lowering in Type 2 DiabetesA Systematic Review and Meta-analysis. JAMA 2015; 313: 603-615
    CrossrefPubMedSearch in Google Scholar
  • 15 ElSayed N, Aleppo G, Aroda VR. et al. Cardiovascular disease and risk management: Standards of care in Diabetes – 2023. Diabetes Care 2023; 46 (Suppl. 01) S158-S190
    CrossrefPubMedSearch in Google Scholar
  • 16 Parhofer KG, Birkenfeld AL, Krone W. et al. Lipidtherapie bei Patienten mit diabetes mellitus. Diabetologie 2023; 18 (Suppl. 02) S330-S336
    Search in Google Scholar
  • 17 Nissen SE, Lincoff AM, Brennan D. et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388: 1353-1364
    CrossrefPubMedSearch in Google Scholar
  • 18 The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539
    CrossrefPubMedSearch in Google Scholar
  • 19 Balletshofer B, Böckler D, Diener H. et al. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Diabetologie 2022; 17 (Suppl. 02) S354-S364
    Thieme ConnectSearch in Google Scholar
  • 20 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337
    CrossrefPubMedSearch in Google Scholar
  • 21 ElSayed N, Aleppo G, Aroda VR. et al. Glycemic Targets: Standards of Care in Diabetes – 2023. Diabetes Care 2023; 46 (Suppl. 01) S97-S110
    CrossrefPubMedSearch in Google Scholar
  • 22 Nationale VersorgungsLeitlinie Typ-2-Diabetes (2021). Accessed April 16, 2024 at: www.leitlinien.de/themen/diabetes/pdf/diabetes-2aufl-vers1.pdf
  • 23 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
    CrossrefPubMedSearch in Google Scholar
  • 24 Frias JP. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Rev Endocrinol Metab 2023; 18: 111-130
    CrossrefPubMedSearch in Google Scholar
  • 25 KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International 2022; 102 (Suppl. 05) S1-S127
    CrossrefPubMedSearch in Google Scholar
  • 26 ElSayed N, Aleppo G, Aroda VR. et al. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes – 2023. Diabetes Care 2023; 46 (Suppl. 01) S191-S202
    CrossrefPubMedSearch in Google Scholar
  • 27 Davies MJ, Aroda VR, Collins BS. et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65: 1925-1966
    CrossrefPubMedSearch in Google Scholar